What Is the Difference Between an SAE, AE, and UADE in Clinical Trials?
Adverse events (AEs) are untoward medical occurrences in participants receiving a study intervention, regardless of whether they’re related to the study. Serious adverse
Adverse events (AEs) are untoward medical occurrences in participants receiving a study intervention, regardless of whether they’re related to the study. Serious adverse
What impact will advancements in artificial intelligence (AI) have on national security and global public health issues, particularly when it
FDA’s 2024 draft guidance signals broader expectations for data monitoring committee (DMC) independence, communication, documentation, and sponsor decision-making. For sponsors and contract research organizations (CROs), now is
Understanding the regulatory foundation behind translated informed consent documents and why many institutional review boards (IRBs) require certificates or attestations of translation.
Gene therapies and gene-based therapeutics are giving way to a new era of interventional genetics. Integrated ethics review and biosafety review have developed into an operational advantage to facilitate this
Cardiovascular disease remains a worldwide challenge, causing undue strain on the health system and contributing substantial patient burden. For decades, our medical response has been
IRB approval is a critical milestone in clinical research, but it isn’t the end of the oversight process. For sponsors, approval marks
Rethinking oversight as clinical trials become more data-driven and algorithm-informed As artificial intelligence (AI) becomes more embedded in clinical trial
Institutional review board (IRB) approval is a critical milestone in clinical research, but it can also become a source of
Multisite research and clinical trials increasingly rely on a single IRB (sIRB) for review. This increase reflects federal mandates, sponsor expectations, and the operational realities of modern multisite or cooperative research. For institutions with a local
A strong protocol and well-drafted consent form are essential, but they are not enough on their own to support a
Let me start with a question I get more and more frequently from research sites as mRNA continues to expand